Advertisement

Treatments in Endocrinology

, Volume 2, Issue 1, pp 11–21 | Cite as

Insulin Pump Therapy in Childhood Diabetes Mellitus

Guidelines For Use
  • William V. Tamborlane
  • Linda P. Fredrickson
  • JoAnn H. Ahern
Therapy in Practice

Abstract

The current goals for the therapy of children and adolescents with type 1 diabetes mellitus are to achieve near-normal glycemia, minimize the risk of severe hypoglycemia, limit excessive weight gain while achieving adequate growth, improve quality of life for both the patients and their families, and delay or prevent vascular complications. Insulin pump therapy provides a treatment option that can significantly aid in achieving all of these goals across all age ranges of pediatric patients. Continuous subcutaneous insulin infusion (CSII) pump therapy can provide greater flexibility in the timing of meals and snacks, has programmable basal rates to optimize overnight glycemic control, can reduce the risk of exercise-induced hypoglycemia, and enhances the ability of the patient and the family members to achieve acceptable diabetes control. In pediatrie patients, CSII has been shown to reduce both glycosylated hemoglobin levels and the frequency of severe hypoglycemia without increasing the risk of diabetic ketoacidosis. The effectiveness of CSII, improvements in pump technology, and the availability of very rapid-acting insulin analogs have fueled a dramatic increase in the use of this therapy.

This review presents practical guidelines for the selection of patients, initiation of treatment and patient education, as well as guidelines for use while exercising and at school. Keys to the success of CSII are to have a multidisciplinary team of clinicians who are expert in the care of children with diabetes, and patients and families who are able to carry out the tasks of intensive treatment, including self-monitoring of blood glucose levels, carbohydrate counting, and infusion pump management. Patients and parents need to be able to recognize and treat hypoglycemia, and prevent the development of ketoacidosis. School personnel need to be involved in the treatment plan and individual algorithms developed for periods of extra exercise and activity. The recent introduction of methods for continuous glucose monitoring provides a new means to optimize the basal and bolus capabilities of CSII and offers hope for the development of a feedback-controlled artificial pancreas.

Keywords

HbA1c Level Insulin Aspart Insulin Lispro Continuous Subcutaneous Insulin Infusion Insulin Pump 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979; 300: 573–8PubMedCrossRefGoogle Scholar
  2. 2.
    Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; 1: 204–7PubMedCrossRefGoogle Scholar
  3. 3.
    Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326–9PubMedCrossRefGoogle Scholar
  4. 4.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRefGoogle Scholar
  5. 5.
    The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and long-term complications in adolescents with insulin-dependent diabetes mellitus. J Pediatr 1994; 125: 177–88CrossRefGoogle Scholar
  6. 6.
    DCCT/EDIC Research Group. Prolonged beneficial effects of intensive therapy of diabetes during adolescence: microvascular outcomes four years after conclusion of the Diabetes Control and Complications Trial. J Pediatr 2001; 139: 804–12CrossRefGoogle Scholar
  7. 7.
    The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995; 18: 1468–78CrossRefGoogle Scholar
  8. 8.
    Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a “new” way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779–84PubMedCrossRefGoogle Scholar
  9. 9.
    Zinman B, Tildesley H, Chiasson J-L, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440–3PubMedCrossRefGoogle Scholar
  10. 10.
    Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28),Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402PubMedCrossRefGoogle Scholar
  11. 11.
    Ahern JAH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002; 3: 10–5PubMedCrossRefGoogle Scholar
  12. 12.
    de Beaufort CE, Houtzagers CMGJ, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989; 6: 766–71PubMedCrossRefGoogle Scholar
  13. 13.
    Tubiana-Rufi N, deLonlay P, Block J, et al. Remission of severe hypoglycemia incidents in young diabetic children treated with subcutaneous infusion. Arch Pediatr 1996; 3: 969–76PubMedCrossRefGoogle Scholar
  14. 14.
    Buckingham BA, Paguntalan H, Fassl B, et al. Continuous subcutaneous insulin infusion (CSII) in children under five years of age [abstract]. Diabetes 2001; 50Suppl. 2: A107Google Scholar
  15. 15.
    Maniatis AK, Klingensmith GJ, Slover RH, et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107: 351–6PubMedCrossRefGoogle Scholar
  16. 16.
    White NH, Hollander AS, Sadler M, et al. Risks and benefits of continuous subcutaneous insulin infusion (CSII) therapy in children [abstract]. Diabetes 2001; 50Suppl. 2: A66Google Scholar
  17. 17.
    Celona-Jacobs N, Weinzimer SA, Rearson M, et al. Insulin pump therapy in children: a cautionary tale [abstract]. Diabetes 2001; 50Suppl. 2: A67Google Scholar
  18. 18.
    Laffel L, Loughlin C, Ramchandani N, et al. Glycemic challenges of pump therapy (CSII) in youth with type 1 diabetes (T1DM) [abstract]. Diabetes 2001; 50Suppl. 2: A66Google Scholar
  19. 19.
    Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 199–204PubMedCrossRefGoogle Scholar
  20. 20.
    Kaufman FR, Kim C, Halvorson M, et al. Use of insulin pump therapy at nighttime only for children 7–10 years of age with type 1 diabetes. Diabetes Care 2000; 23: 579–82PubMedCrossRefGoogle Scholar
  21. 21.
    Kaufman FR, Halvorson M, Carpenter S, et al. Insulin pump therapy in young children with diabetes. Diabetes Spectrum 2001; 14: 84–9CrossRefGoogle Scholar
  22. 22.
    Boland E. Teens pumping it up. 2nd ed. Sylmar (CA): MiniMed, 1998Google Scholar
  23. 23.
    Kaufman FR, Halvorson M, Miller D, et al. Insulin pump therapy in type 1 pediatric patients: now and into the year 2000. Diabetes Metab Res Rev 1999; 15: 338–52PubMedCrossRefGoogle Scholar
  24. 24.
    Fredrickson F, Rubin RR, Rubin S. Optimal pumping: a guide to good health with diabetes. Northridge (CA): MiniMed Inc, 2001Google Scholar
  25. 25.
    Ahern JA, Ramchandani N, Cooper J, et al. Using a primary nurse manager to implement DCCT recommendations in a large pediatrie program. Diabetes Educ 2000; 26: 990–4PubMedCrossRefGoogle Scholar
  26. 26.
    Boland EA, Ahern JH, Ahern JA, et al. Pumps and kids: basal requirements for excellent metabolic control [abstract]. Diabetes 2002; 51 Suppl. 2: AllGoogle Scholar
  27. 27.
    Ahern JA, Gatcomb PM, Held NA, et al. Exaggerated hyperglycemia after a pizza meal in well-controlled diabetes. Diabetes Care 1993; 16: 578–80PubMedCrossRefGoogle Scholar
  28. 28.
    Grey M, Boland EA, Davidson M, et al. Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr 2000; 137: 107–13PubMedCrossRefGoogle Scholar
  29. 29.
    Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause [abstract]. Diabetes Care 2001; 24: 174PubMedCrossRefGoogle Scholar
  30. 30.
    Attia N, Jones TW, Holcombe J, et al. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21:817–21PubMedCrossRefGoogle Scholar
  31. 31.
    Davis EA, Keating B, Byrne GC, et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997; 20: 22–5PubMedCrossRefGoogle Scholar
  32. 32.
    Garg SK, Potts RO, Ackerman NR, et al. Correlation of fingerstick blood glucose measurements with GlucoWatch Biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999; 22: 1708–14PubMedCrossRefGoogle Scholar
  33. 33.
    Boland E, Monsod T, DeLucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from three days of continuous glucose sensing in pediatrie patients with type I diabetes. Diabetes Care 2001; 24:1858–62PubMedCrossRefGoogle Scholar
  34. 34.
    Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatrie type 1 diabetic subjects. Diabetes Care 2001; 24: 2030–4PubMedCrossRefGoogle Scholar
  35. 35.
    Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46: 183–90PubMedCrossRefGoogle Scholar
  36. 36.
    Albisser AM, Leibel BS, Ewart TG, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23: 397–404PubMedGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • William V. Tamborlane
    • 1
  • Linda P. Fredrickson
    • 2
  • JoAnn H. Ahern
    • 1
  1. 1.Department of Pediatrics and the Children’s Clinical Research CenterYale University School of MedicineNew HavenUSA
  2. 2.Medtronic MiniMedNorthridgeUSA

Personalised recommendations